About NovoCure (NASDAQ:NVCR)
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700
Debt
Debt-to-Equity Ratio0.86%
Current Ratio4.88%
Quick Ratio4.44%
Price-To-Earnings
Trailing P/E Ratio-35.21
Forward P/E Ratio-49.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$177.03 million
Price / Sales12.59
Cash FlowN/A
Price / CashN/A
Book Value$1.27 per share
Price / Book19.41
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-61,660,000.00
Net Margins-34.83%
Return on Equity-51.74%
Return on Assets-23.51%
Miscellaneous
Employees495
Outstanding Shares90,400,000
NovoCure (NASDAQ:NVCR) Frequently Asked Questions
What is NovoCure's stock symbol?
NovoCure trades on the NASDAQ under the ticker symbol "NVCR."
How were NovoCure's earnings last quarter?
NovoCure (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, February, 22nd. The medical equipment provider reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The medical equipment provider earned $53.66 million during the quarter, compared to the consensus estimate of $53.17 million. NovoCure had a negative net margin of 34.83% and a negative return on equity of 51.74%. The company's quarterly revenue was up 77.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.26) EPS. View NovoCure's Earnings History.
When is NovoCure's next earnings date?
What price target have analysts set for NVCR?
5 equities research analysts have issued 1 year price targets for NovoCure's shares. Their predictions range from $14.00 to $32.00. On average, they expect NovoCure's share price to reach $21.00 in the next twelve months. View Analyst Ratings for NovoCure.
What are Wall Street analysts saying about NovoCure stock?
Here are some recent quotes from research analysts about NovoCure stock:
- 1. Mizuho analysts commented, "We now anticipate a potential FDA approval for the mesothelioma indication before year-end 2018 given the company’s filing under Humanitarian Device Exemption. We updated our model to reflect revenues from mesothelioma in the coming years and raise our PT to $32." (4/18/2018)
- 2. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (2/28/2018)
- 3. JPMorgan Chase analysts commented, "NVCR’s 1Q report (slides here) was largely uneventful as the co continues to make progress with the Optune launch. 1Q net revenues were $35M vs. consensus of $41M (though we note the cash vs. accrual accounting makes net revenue hard to predict). There were 1,266 active patients on therapy at 1Q-end (+16% q/q), ahead of our 1,226 estimate. We are encouraged by the progress here, though will be looking for momentum to continue to build following recent reimbursement wins, NCCN guidelines, as well as impressive follow-up survival data from the pivotal EF-14 trial." (5/1/2017)
Who are some of NovoCure's key competitors?
Some companies that are related to NovoCure include Penumbra (PEN), Haemonetics (HAE), NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY) and Cardiovascular Systems (CSII).
Who are NovoCure's key executives?
NovoCure's management team includes the folowing people:
- Mr. William F. Doyle, Exec. Chairman (Age 56)
- Mr. Asaf Danziger, CEO & Director (Age 52)
- Mr. Kinyip Gabriel Leung, Vice Chairman & Chairman of the Global Commercialization Team (Age 56)
- Prof. Yoram Palti, Founder, CTO & Director (Age 80)
- Mr. Wilhelmus C. M. Groenhuysen, CFO & Principal Accounting Officer (Age 60)
Has NovoCure been receiving favorable news coverage?
Media headlines about NVCR stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NovoCure earned a news impact score of 0.15 on Accern's scale. They also gave news coverage about the medical equipment provider an impact score of 45.30 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of NovoCure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NovoCure's stock price today?
One share of NVCR stock can currently be purchased for approximately $24.65.
How big of a company is NovoCure?
NovoCure has a market capitalization of $2.23 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. NovoCure employs 495 workers across the globe.
How can I contact NovoCure?
NovoCure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]
MarketBeat Community Rating for NovoCure (NVCR)
MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
NovoCure (NASDAQ:NVCR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NovoCure (NASDAQ NVCR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 42.83%
NovoCure (NASDAQ NVCR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/18/2018 | Michael J Ambrogi | COO | Sell | 40,000 | $23.03 | $921,200.00 | 166,558 |  |
| 4/18/2018 | Yoram Palti | Insider | Sell | 44,072 | $23.65 | $1,042,302.80 | 116,451 | |
| 4/3/2018 | Yoram Palti | Insider | Sell | 60,000 | $20.32 | $1,219,200.00 | | |
| 3/29/2018 | Yoram Palti | CTO | Sell | 30,000 | $21.67 | $650,100.00 | | |
| 2/23/2018 | Michael J Ambrogi | COO | Sell | 8,458 | $19.83 | $167,722.14 | 105,288 | |
| 2/23/2018 | Todd Christopher Longsworth | General Counsel | Sell | 6,591 | $19.83 | $130,699.53 | 26,665 | |
| 2/23/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 13,351 | $19.83 | $264,750.33 | 252,412 | |
| 1/29/2018 | Asaf Danziger | CEO | Sell | 13,974 | $24.02 | $335,655.48 | 356,790 | |
| 1/29/2018 | Todd Christopher Longsworth | General Counsel | Sell | 11,630 | $24.00 | $279,120.00 | 16,628 | |
| 1/24/2018 | Asaf Danziger | CEO | Sell | 20,848 | $22.10 | $460,740.80 | 387,820 | |
| 1/16/2018 | Asaf Danziger | CEO | Sell | 14,900 | $22.20 | $330,780.00 | 398,068 | |
| 1/12/2018 | Asaf Danziger | CEO | Sell | 336,420 | $22.33 | $7,512,258.60 | 435,863 | |
| 1/11/2018 | Eilon D Kirson | Insider | Sell | 25,320 | $22.00 | $557,040.00 | 3,181 | |
| 1/9/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 31,132 | $21.02 | $654,394.64 | 240,210 | |
| 1/4/2018 | Wilhelmus Cm Groenhuysen | CFO | Sell | 28,868 | $21.03 | $607,094.04 | 268,568 | |
| 11/13/2017 | Yoram Palti | Insider | Sell | 30,000 | $17.13 | $513,900.00 | | |
| 11/9/2017 | Yoram Palti | CTO | Sell | 30,000 | $18.25 | $547,500.00 | | |
| 11/7/2017 | Yoram Palti | Insider | Sell | 60,000 | $21.06 | $1,263,600.00 | | |
| 11/6/2017 | Asaf Danziger | CEO | Sell | 6,919 | $22.00 | $152,218.00 | | |
| 11/3/2017 | Asaf Danziger | CEO | Sell | 2,300 | $22.00 | $50,600.00 | 756,024 | |
| 11/3/2017 | Eilon D Kirson | Insider | Sell | 3,400 | $22.00 | $74,800.00 | 40,701 | |
| 11/3/2017 | Michael J Ambrogi | COO | Sell | 1,200 | $22.00 | $26,400.00 | 24,987 | |
| 11/2/2017 | Yoram Palti | CTO | Sell | 30,000 | $21.78 | $653,400.00 | | |
| 11/1/2017 | Asaf Danziger | CEO | Sell | 15,866 | $22.01 | $349,210.66 | 774,040 | |
| 11/1/2017 | Eilon D Kirson | Insider | Sell | 22,269 | $22.01 | $490,140.69 | 63,120 | |
| 11/1/2017 | Michael J Ambrogi | COO | Sell | 24,327 | $22.01 | $535,437.27 | 49,514 | |
| 9/25/2017 | Asaf Danziger | CEO | Sell | 900 | $22.05 | $19,845.00 | 774,190 | |
| 9/14/2017 | Asaf Danziger | CEO | Sell | 37,272 | $22.01 | $820,356.72 | 776,862 | |
| 9/13/2017 | Asaf Danziger | CEO | Sell | 35,500 | $22.01 | $781,355.00 | 776,862 | |
| 7/11/2017 | Asaf Danziger | CEO | Sell | 7,383 | $19.95 | $147,290.85 | 462,765 | |
| 7/10/2017 | Asaf Danziger | CEO | Sell | 274,359 | $18.07 | $4,957,667.13 | 668,865 | |
| 7/6/2017 | Asaf Danziger | CEO | Sell | 160,138 | $18.14 | $2,904,903.32 | 899,462 | |
| 7/5/2017 | Asaf Danziger | CEO | Sell | 155,088 | $18.14 | $2,813,296.32 | 899,462 | |
| 6/26/2017 | Pomona Capital Vii Fund Invest | Major Shareholder | Sell | 1,072,532 | $17.35 | $18,608,430.20 | | |
| 6/21/2017 | Eilon D Kirson | Insider | Sell | 66,361 | $16.78 | $1,113,537.58 | 222,722 | |
| 6/19/2017 | Asaf Danziger | CEO | Sell | 124,720 | $15.51 | $1,934,407.20 | 896,917 | |
| 6/19/2017 | Eilon D Kirson | Insider | Sell | 15,000 | $15.06 | $225,900.00 | 289,083 | |
| 6/16/2017 | Asaf Danziger | CEO | Sell | 42,457 | $15.15 | $643,223.55 | 1,030,849 | |
| 6/14/2017 | Asaf Danziger | CEO | Sell | 94,102 | $15.22 | $1,432,232.44 | 1,069,496 | |
| 6/12/2017 | Asaf Danziger | CEO | Sell | 180,601 | $15.13 | $2,732,493.13 | 1,163,296 | |
| 6/12/2017 | Eilon D Kirson | Insider | Sell | 20,956 | $15.03 | $314,968.68 | 319,083 | |
| 6/5/2017 | Yoram Palti | Insider | Sell | 3,825 | $13.82 | $52,861.50 | | |
| 6/2/2017 | Yoram Palti | Insider | Sell | 8,000 | $13.27 | $106,160.00 | 7,825 | |
| 5/31/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.49 | $99,920.00 | 15,825 | |
| 5/26/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.88 | $103,040.00 | 23,825 | |
| 5/24/2017 | Yoram Palti | Insider | Sell | 4,000 | $13.15 | $52,600.00 | 29,256 | |
| 5/23/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.73 | $93,840.00 | 35,825 | |
| 5/19/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.39 | $91,120.00 | 43,825 | |
| 5/17/2017 | Yoram Palti | Insider | Sell | 4,000 | $11.47 | $45,880.00 | 47,825 | |
| 5/16/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.05 | $96,400.00 | 55,825 | |
| 5/12/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.79 | $94,320.00 | 63,825 | |
| 5/10/2017 | Yoram Palti | Insider | Sell | 8,000 | $12.29 | $98,320.00 | 71,825 | |
| 5/8/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.82 | $94,560.00 | 79,825 | |
| 5/4/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.42 | $91,360.00 | 87,825 | |
| 5/2/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.64 | $93,120.00 | 95,825 | |
| 4/28/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.25 | $90,000.00 | 103,825 | |
| 4/26/2017 | Yoram Palti | Insider | Sell | 8,000 | $10.78 | $86,240.00 | 111,825 | |
| 4/24/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.26 | $90,080.00 | 119,825 | |
| 4/20/2017 | Yoram Palti | Insider | Sell | 8,000 | $11.24 | $89,920.00 | 127,825 | |
| 4/18/2017 | Yoram Palti | Insider | Sell | 16,000 | $10.64 | $170,240.00 | 143,825 | |
| 4/17/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.77 | $43,080.00 | 143,825 | |
| 4/13/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.43 | $41,720.00 | 143,825 | |
| 4/12/2017 | Yoram Palti | CTO | Sell | 4,000 | $10.72 | $42,880.00 | 143,825 | |
| 3/14/2017 | Gert L Perlhagen | Director | Buy | 125,000 | $6.93 | $866,250.00 | 6,125,000 | |
| 12/22/2016 | Michael J Ambrogi | COO | Sell | 27,500 | $8.27 | $227,425.00 | 139,084 | |
| 12/20/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $8.62 | $172,400.00 | 179,084 | |
| 12/19/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $8.76 | $175,200.00 | 179,084 | |
| 12/16/2016 | Michael J Ambrogi | COO | Sell | 40,000 | $8.93 | $357,200.00 | 219,084 | |
| 12/14/2016 | Michael J Ambrogi | COO | Sell | 40,000 | $8.97 | $358,800.00 | 259,084 | |
| 12/12/2016 | Michael J Ambrogi | COO | Sell | 15,000 | $9.01 | $135,150.00 | 289,084 | |
| 12/8/2016 | Michael J Ambrogi | COO | Sell | 10,000 | $8.30 | $83,000.00 | 299,084 | |
| 12/6/2016 | Michael J Ambrogi | COO | Sell | 10,000 | $8.24 | $82,400.00 | 309,084 | |
| 8/5/2016 | Gert L Perlhagen | Director | Sell | 676,576 | $1.85 | $1,251,665.60 | 676,576 | |
| 6/8/2016 | Michael J Ambrogi | COO | Sell | 20,000 | $12.24 | $244,800.00 | 324,084 | |
| 3/3/2016 | Asaf Danziger | CEO | Buy | 10,000 | $15.00 | $150,000.00 | 933,557 | |
| 3/3/2016 | Robert J Mylod Jr | Director | Buy | 20,000 | $15.78 | $315,600.00 | 148,114 | |
(Data available from 1/1/2013 forward)
NovoCure (NASDAQ NVCR) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | NovoCure (NVCR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 22 at 7:48 AM |
 | BRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln
www.reuters.com - April 20 at 5:30 PM |
| NovoCure (NVCR) Insider Sells $1,042,302.80 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM |
| NovoCure (NVCR) COO Sells $921,200.00 in Stock
www.americanbankingnews.com - April 19 at 7:18 PM |
| NovoCure (NVCR) Upgraded at Deutsche Bank
www.americanbankingnews.com - April 19 at 10:01 AM |
 | Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research ...
globenewswire.com - April 19 at 8:07 AM |
 | Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma
finance.yahoo.com - April 19 at 8:07 AM |
| Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - April 19 at 8:07 AM |
| NovoCure (NVCR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 2:34 AM |
| NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
finance.yahoo.com - April 18 at 5:53 PM |
| NovoCure (NVCR) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 18 at 9:00 AM |
| BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma
www.reuters.com - April 17 at 6:06 PM |
| NovoCure (NVCR) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 17 at 1:54 PM |
 | What's Happening With These Medical Equipment Stocks? -- Natus Medical, NovoCure, NuVasive, and Nxstage Medical
www.prnewswire.com - April 17 at 8:16 AM |
 | Novocure (NVCR) Announces Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
www.streetinsider.com - April 17 at 8:16 AM |
| Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
finance.yahoo.com - April 17 at 8:16 AM |
| NovoCure (NVCR) Expected to Announce Quarterly Sales of $56.79 Million
www.americanbankingnews.com - April 17 at 3:28 AM |
| Analysts Anticipate NovoCure (NVCR) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 15 at 1:23 PM |
| BidaskClub Upgrades NovoCure (NVCR) to Strong-Buy
www.americanbankingnews.com - April 14 at 9:51 PM |
| NovoCure (NVCR) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 14 at 6:54 PM |
| Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 13 at 5:41 PM |
| Insider Selling: NovoCure (NVCR) Insider Sells 60,000 Shares of Stock
www.americanbankingnews.com - April 4 at 10:39 PM |
| Novocure (NVCR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:54 PM |
| Is NovoCure Limited’s (NASDAQ:NVCR) Balance Sheet A Threat To Its Future?
finance.yahoo.com - April 3 at 5:43 PM |
| Novocure to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 3 at 8:10 AM |
| Insider Selling: Novocure Ltd (NVCR) CTO Sells 30,000 Shares of Stock
www.americanbankingnews.com - April 2 at 4:14 PM |
| Zacks: Brokerages Expect Novocure Ltd (NVCR) Will Announce Quarterly Sales of $56.79 Million
www.americanbankingnews.com - March 31 at 2:28 AM |
| -$0.13 EPS Expected for Novocure Ltd (NVCR) This Quarter
www.americanbankingnews.com - March 29 at 5:23 PM |
| Novocure Ltd (NVCR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 10:17 AM |
| Contrasting Helios and Matheson Analytics (HMNY) & Novocure (NVCR)
www.americanbankingnews.com - March 27 at 9:18 PM |
| BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide
www.reuters.com - March 20 at 5:25 PM |
| NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
finance.yahoo.com - March 20 at 5:25 PM |
 | Active-Investors: Wired News - NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018
www.finanznachrichten.de - March 19 at 5:26 PM |
| Wired News – NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018
finance.yahoo.com - March 19 at 8:10 AM |
| Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR)
finance.yahoo.com - March 15 at 6:24 PM |
| Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
finance.yahoo.com - March 15 at 8:06 AM |
| Novocure (NVCR) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 10 at 4:59 PM |
| Analyzing Madrigal Pharmaceuticals (MDGL) and Novocure (NVCR)
www.americanbankingnews.com - March 8 at 2:24 PM |
| 1,055,000 Shares in Novocure Ltd (NVCR) Acquired by Tamarack Advisers LP
www.americanbankingnews.com - March 6 at 10:31 AM |
| Novocure Ltd (NVCR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 3 at 12:16 PM |
| EAM Investors LLC Buys New Stake in Novocure Ltd (NVCR)
www.americanbankingnews.com - March 1 at 12:10 PM |
| Novocure (NVCR) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 28 at 10:52 AM |
| Tumor-treating biotech Novocure turns its attention to lu...
finance.yahoo.com - February 27 at 6:02 PM |
| Cramer Remix: It's time to investigate risky VIX-related trading products
finance.yahoo.com - February 27 at 6:02 PM |
| Novocure Ltd (NVCR) Position Boosted by Cortina Asset Management LLC
www.americanbankingnews.com - February 27 at 1:40 PM |
| Novocure Sees Unusually High Options Volume (NVCR)
www.americanbankingnews.com - February 27 at 8:38 AM |
| Medical Equipment Stocks' Research Reports Released on Nevro, NovoCure, NuVasive, and Nxstage Medical - PR Newswire (press release)
www.prnewswire.com - February 27 at 8:08 AM |
| Michael J. Ambrogi Sells 8,458 Shares of Novocure Ltd (NVCR) Stock
www.americanbankingnews.com - February 26 at 6:50 PM |
| Novocure Ltd (NVCR) General Counsel Sells $130,699.53 in Stock
www.americanbankingnews.com - February 26 at 6:50 PM |
| Novocure Ltd (NVCR) CFO Sells $264,750.33 in Stock
www.americanbankingnews.com - February 26 at 6:34 PM |
NovoCure (NASDAQ:NVCR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NovoCure (NASDAQ:NVCR) Income Statement, Balance Sheet and Cash Flow Statement
NovoCure (NASDAQ NVCR) Stock Chart for Sunday, April, 22, 2018
Loading chart…
